BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Viola A, Monterubbianesi R, Scalisi G, Furfaro F, Rea M, Saibeni S, Aratari A, Bringiotti R, Casella G, Cantoro L, Frankovic I, Calella F, Pugliese D, Orlando S, Samperi L, Cappello M, Mocci G, Manetti N, Annese V, Privitera AC, Inserra G, Caprioli F, D’incà R, Principi M, Papi C, Castiglione F, Danese S, Ardizzone S, Bossa F, Kohn A, Manguso F, Alibrandi A, Fiorino G, Armuzzi A, Fries W. Late-onset Crohn’s disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammatory Bowel Disease ‘AGED’ study. European Journal of Gastroenterology & Hepatology 2019;31:1361-9. [DOI: 10.1097/meg.0000000000001546] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Belvedere A, Scoglio R, Viola A, Costantino G, Sitibondo A, Muscianisi M, Inferrera S, Alibrandi A, Fries W. A real world investigation on prevalence, clinical features, and therapy of inflammatory bowel disease in the city of Messina, Italy. Acta Biomed 2021;92:e2021161. [PMID: 33988169 DOI: 10.23750/abm.v92i2.9593] [Reference Citation Analysis]
2 Ministro P, Dias CC, Portela F, Fernandes S, Bernardo S, Pires F, Lago P, Rosa I, Trindade E, Alves C, Correia L, Magro F. Age at Diagnosis Is Determinant for the Outcome of Inflammatory Bowel Disease: Is It a Myth? Clin Transl Gastroenterol 2021;12:e00309. [PMID: 33587489 DOI: 10.14309/ctg.0000000000000309] [Reference Citation Analysis]
3 Ibraheim H, Samaan MA, Srinivasan A, Brain O, Digby-Bell J, Irving PM, Norman I, Jawad I, Biedermann J, Ibarra A, Kok KB, Parkes G, Rimmer J, Compot E, Parkes M, Segal J, Oppong P, Hart A, Hayee B, Powell N. Effectiveness and safety of vedolizumab in inflammatory bowel disease patients aged 60 and over: an observational multicenter UK experience. Ann Gastroenterol 2020;33:170-7. [PMID: 32127738 DOI: 10.20524/aog.2020.0447] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
4 Calafat M, Mañosa M, Ricart E, Nos P, Iglesias-Flores E, Vera I, López-SanRomán A, Guardiola J, Taxonera C, Mínguez M, Martín-Arranz MD, de Castro L, de Francisco R, Rivero M, Garcia-Planella E, Calvet X, García-López S, Márquez L, Gomollón F, Barrio J, Esteve M, Muñoz F, Gisbert JP, Gutiérrez A, Hinojosa J, Argüelles-Arias F, Busquets D, Bujanda L, Pérez-Calle JL, Sicilia B, Merino O, Martínez P, Bermejo F, Lorente R, Barreiro-de Acosta M, Rodríguez C, García-Sepulcre MF, Monfort D, Cañete F, Domènech E; ENEIDA Study Group of GETECCU. Risk of immunomediated adverse events and loss of response to infliximab in elderly patients with inflammatory bowel disease. A cohort study of the ENEIDA registry. J Crohns Colitis 2021:jjab213. [PMID: 34864947 DOI: 10.1093/ecco-jcc/jjab213] [Reference Citation Analysis]